VTVT management to participate in September investor conferences
VTVT announced management will participate in September investor conferences. The company is advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D).
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
VTVT - vTv Therapeutics to Participate in September Investor Conferences
VTVT - vTv Therapeutics to Participate in September Investor Conferences